Intelligence Login
Inventor Portal
  • Services
  • About Us
  • News & Media
    • Reports
    • Videos
    • Articles
    • Legal Articles
    • Case Studies
    • Press Releases
  • Contact Us
  • Inventor Portal
  • Intelligence Login
Contact

ClearSign Technologies Announces Order for Multi Heater Project for Texas Petrochemical Facility

by Staff | Jul 17, 2024 | Press Releases

Project Comprised of 26 ClearSign Core™ Process Burners in Four Heaters Order Received from Birwelco USA Inc. for Fortune 500 Global Chemical Company TULSA, Okla., July 17, 2024 /PRNewswire/ — ClearSign Technologies Corporation (Nasdaq: CLIR)...

MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies

by Staff | Jul 11, 2024 | Press Releases

Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) — MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and...

MDB Capital Collaborates with Mayo Clinic to Advance Anti-Senescence Platform

by Staff | Jul 8, 2024 | Press Releases

ADDISON, Texas, July 08, 2024 (GLOBE NEWSWIRE) — MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announced a collaboration through a patent and...

New PatentVest Pulse Report Delves into Transformative Innovations in MASH Diagnostics

by Staff | Jul 8, 2024 | Press Releases

Dallas, Texas, July 8, 2024 – PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC)...

Recent Posts

  • What Is OpenAI Actually Patenting?
  • Why Patent Prosecution Is Ready for AI
  • The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1
  • The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity
  • The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.

Recent Comments

    Archives

    • July 2026
    • June 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • October 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • February 2024
    • January 2024
    • November 2023
    • October 2023
    • June 2023
    • May 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022

    Categories

    • Case Studies
    • Legal Reports
    • PatentVest Pulse
    • Press Releases
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    ServicesAboutNews & Media

    Terms of Use  |       © 2026 – PatentVest, Inc.

    • Follow